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ABSTRACT
We investigated the impact of time interval, primary versus metastatic biopsy site, variant
allele  fraction  (VAF),  and  histology  on  concordance  of  KRAS alterations  in  tissue  versus
circulating tumor DNA (ctDNA), and association of concordance with survival. Blood and tissue
were  evaluated  by  next-generation  sequencing  (NGS)  in  433  patients  with  diverse  cancers.
Altogether, 101 patients (23.3%) had KRAS alterations: 56, ctDNA (12.9%); 81, tissue (18.7%);
and 36, both (8.3%). The overall blood and tissue concordance rate for  KRAS alterations was
85%, but was mainly driven by the large negative/negative subset. Therefore, specificity of one
test for the other was high (88.1-94.3%), while sensitivity was not high (44.4-64.3%) and was
lower still in patients with >6 versus ≤2 months between blood and tissue sampling (31.0-40.9%
versus 51.2-84.0%) (P=0.14 time interval-dependent sensitivity  of  blood for  tissue;  P=0.003,
tissue  for  blood).  Positive  concordance  rate  for  KRAS  alterations  was  57.1%  versus  27.4%
(colorectal versus non-colorectal cancer) (P=0.01), but site of biopsy (primary versus metastatic)
and  VAF  (%ctDNA)  was  not  impactful.  The  presence  of  KRAS alterations  in  both  tests  was
independently  associated  with  shorter  survival  from  diagnosis  (hazard  ratio,  1.72;  95%
confidence interval, 1.04-2.86) and from recurrent/metastatic disease (1.70; 1.03-2.81). Positive
concordance of KRAS alterations between ctDNA and tissue was negatively affected by a longer
time period between blood and tissue sampling and was higher in colorectal cancer than in other
malignancies. The presence of  KRAS alterations in both tests was an independent prognostic
factor for poor survival.  
Key words: KRAS; circulating tumor DNA; next-generation sequencing; survival.
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NOVELTY AND IMPACT
Positive  concordance  between  ctDNA  and  tissue  DNA  for  KRAS alterations  was  inversely
associated with time interval between blood and tissue sampling and was higher in colorectal
versus  non-colorectal  cancer.  In  multivariate  analysis,  concordant  KRAS alterations  (versus
discordant  KRAS alteration status or no  KRAS alterations) in blood and tissue correlated with
shorter survival, suggesting complementary clinical utility for ctDNA and tissue DNA sequencing
techniques in prognostication.  
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INTRODUCTION
KRAS is  a  protein  in  the  mitogen-activated  protein  kinase  (MPAK)  pathway  that  is
responsible  for  various  aspects  of  cell  growth  and  regulation,  including  cell  proliferation,
apoptosis,  and differentiation. Alterations in the  KRAS oncogene occur frequently and play a
major role in many human cancers.1,  2  As an example, in pancreatic ductal adenocarcinoma,
oncogenic KRAS is present in more than 90% of cases.2, 3 KRAS is also present in 30%-40% of all
colorectal cancer cases and is associated with decreased survival.1, 2
Investigation of  molecular alterations in cancerous tumors has created a new wave of
personalized cancer medicine that uses targeted cancer therapies matched to a patient’s specific
molecular alterations.4 Recent research has shown that advancements in genomic testing has led
to higher response rates to treatment in patients with advanced cancers.5 With the availability of
these multi-gene panels, malignant tissues have been found to harbor multiple alterations that
may differ from patient to patient and, hence, require customized combination therapies 5 In the
case of  KRAS, mutations may also serve as a negative marker, indicating a contraindication to
epidermal growth factor receptor (EGFR) antibody therapy in colorectal cancer.6, 7
Interrogating  blood-derived  circulating  tumor  DNA (ctDNA)  allows  for  the  detection  of
genetic heterogeneity in cancer without the invasive nature of tissue biopsies.  Solid tumors
release ctDNA into the bloodstream. The amount present or absent in the blood may be an
indicator of tumor burden.8-10 This ctDNA is collected through a liquid biopsy (i.e., a blood draw)
and sequenced in order to identify characterized somatic alterations. Blood-derived ctDNA may
provide valuable molecular data as an adjunct to the tumor biopsy for the following reasons: (i)
tumor biopsies can be complicated procedures with morbidity; (ii) some tumors are not readily
accessible for biopsy; (iii) tissue biopsies can be expensive; (iv) as time elapses, the tissue that
was biopsied may become less representative of the tumor, since cancers evolve; (v) genomics
performed on a tissue biopsy reflects the alterations that are in the small tissue specimen, while
genomics  performed  on  ctDNA  may  reflect  alterations  found  in  shed  DNA  from  multiple
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metastatic sites; and (vi) dynamic changes in ctDNA can occur and reflect response to therapy or
emergence of resistance. In addition, interrogating ctDNA before or after surgery may provide a
predictive tool for risk of recurrence.11, 12 There are also disadvantages to ctDNA as compared to
tissue. For instance, ctDNA is found in only small amounts in the bloodstream, making it difficult
to detect alterations. In addition, ctDNA carrying tumor-specific alterations may represent only a
small fraction of the total genomic alterations in the tumor, since not all cancer-derived DNA may
be shed into the bloodstream. Therefore, variability in concordance rates between blood-derived
ctDNA  samples  and  tissue  samples  can  be  due  to  temporal  and  spatial  factors,  as  well  as
dynamic changes with therapy and disease evolution.
Several studies have investigated the concordance in molecular alterations between tissue
and ctDNA samples. A study conducted in prostate cancer found that, in the majority of patients,
a ctDNA assay was sufficient to identify all driver DNA alterations present in matched metastatic
tissue.13 Other  studies  demonstrated  that,  among  various  cancer  types,  concordance  was
variable with a range of ~70% to ~98%, depending on the gene(s) examined.8,  14,  15 Several
previous studies evaluated the concordance of KRAS alterations between tissue and ctDNA and
found overall concordance to range 67-96%.6, 16-18 These studies did not evaluate the impact of
time interval between tissue biopsy and blood draw, nor did they examine the correlation with
site of biopsy or the association with outcome for discordant versus concordant KRAS alterations.
For this present study, results from tumor biopsies and blood-derived ctDNA biopsies were
used to investigate the level of concordance for altered KRAS among 433 patients with diverse
cancer  types in  order  to  determine temporal  and spatial  effects  on concordance  across  the
spectrum of malignancies, as well  as to ascertain the relationship between concordance and
survival. 
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METHODS
Patients   
The molecular profiles of both liquid and tissue biopsies from 433 consecutive eligible
patients seen at the UC San Diego Moores Cancer Center starting in June 2014 were reviewed
(Supplemental Figure 1).  Demographics  of each of  these patients were provided by chart
review, including, but not limited to age, gender, cancer diagnosis, tumor origin, date of biopsy
report or blood test, date of diagnosis, and survival time. Patients included in the study were
analyzed and consent  obtained as appropriate  in accordance  with  an internal  review board-
approved protocol (NCT02478931). 
Next-Generation Sequencing   
The ctDNA molecular profiles came from patients with diverse cancers and were provided
by  Guardant  Health  Inc.  (http://www.guardanthealth.com/);  tissue  testing  was  performed  by
Foundation  Medicine  (https://www.foundationmedicine.com/genomic-testing#how-does-it-work).
Both laboratories are Clinical Laboratory Improvement Amendment (CLIA)-accredited.
ctDNA testing:  As reported in Lanman and colleagues, 5–30 ng of ctDNA was isolated from
plasma (two 10 ml Streck tubes drawn for each patient) and sequencing libraries were made with
custom in-line barcode molecular tagging and complete sequencing at 15,000× read depth.19
The panels  use  hybrid  capture  followed by  next-generation  sequencing (NGS)  of  the crucial
exons in a panel of 54–73 genes and report all four major types of genomic alterations (indels,
fusions,  point  mutations,  and  copy  number  amplifications).  Post-sequencing  bioinformatics
matches the complementary strands of each barcoded DNA fragment to remove false-positive
results.19 The  variant  allele  fraction  (%ctDNA)  is  calculated  as  the  number  of  mutated  DNA
molecules divided by the total number (mutated plus wild type) of DNA fragments at that allele.
We  used  the  maximum %ctDNA if  a  patient  had  two  different  KRAS alterations,  unless  we
referred to a specific  KRAS  alteration.  The majority of cell-free DNA is wild type; hence, the
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median %ctDNA of somatic alterations is <0.5%. The analytic sensitivity reaches detection of
one to two single-mutant fragments from a 10-ml blood sample (0.1% limit of detection), and the
analytic specificity is greater than 99.9999%.19 
Tissue NGS: Tissue NGS was performed at Foundation Medicine with assay panels of 236 or 315
genes as previously described (Cambridge, MA, www.foundationmedicine.com).20 Average depth
of sequencing was greater than 250x, with 100x at > 99% of exons. This method of sequencing
allows for detection of copy number alterations, gene rearrangements, and somatic mutations
with 99% specificity and >99% sensitivity for base substitutions at ≥5 mutant allele frequency
and  >95%  sensitivity  for  copy  number  alterations.  A  threshold  of  ≥8  copies  for  gene
amplification was used.
Variants of Unknown Significance:  Synonymous alterations and other variants of unknown
significance  (VUS)  were  excluded  and  only  characterized  alterations  were  included  in  the
analysis.21
Defining Concordance 
Concordant alterations between ctDNA blood-derived biopsy samples and tissue biopsy
samples were defined as a KRAS alteration being detected in both samples. If patients had more
than  one  tissue  or  blood  sample,  the  samples  closest  together  were  counted.  Concordance
between tissue DNA and ctDNA was assessed with overall  concordance  rate  and the Kappa
value.  Kappa  values  were  interpreted  by  commonly  used  agreement  categories:  1  (perfect
agreement) to 0 (no agreement [the same as would be expected by chance]). 
Outcome Endpoints and Statistical Analysis 
Difference in overall concordance rate between two groups was compared with Fisher's
exact test to assess statistical significance (P≤0.05). Descriptive characteristics were reported
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for all patients and the most common characterized alterations found in both liquid and tissue
biopsies were highlighted. Patients were then categorized into groups based on whether they
were diagnosed with colorectal cancer or non-colorectal cancers. Survival was examined by the
method of Kaplan Meier; patients still  alive at the last follow up were censored at that time.
Survival time was calculated for three dates of interest; data of diagnosis, date of blood draw for
ctDNA,  and  date  of  metastatic  or  recurrent  disease.  Data  cutoff for  survival  analysis  was
February 22, 2018. Log-rank test was used to compare Kaplan Meier curves. In terms of the
investigation of factors associated with overall  survival  (OS),  variables with  P-value <0.15 in
univariate analysis were included in the multivariate Cox-regression model. Statistical analyses
were performed by coauthor RO using the IBM SPSS version 25.0.
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RESULTS
Patients and molecular alterations
        This study population consisted of 433 patients with diverse cancers who had both ctDNA
and tissue NGS performed. Their median age at diagnosis was 59 years (range, 2 to 91 years)
and 237 patients were women (54.7%) (Table 1).  The most common types of cancers were
gastrointestinal,  lung,  brain,  and breast.  All  but  28 patients  had advanced disease that  was
surgically unresectable, metastatic, or both. 
          In the 433 patients, the most common non-VUS alterations found in both ctDNA and tissue
biopsies were TP53 (ctDNA: 36.7% of patients, tissue: 49.7% of patients), KRAS (ctDNA: 12.9%,
tissue: 18.7%), CDKN2A/B (ctDNA: 1.9%, tissue: 20.3%), and EGFR (ctDNA: 10.6%, tissue: 11.6%)
(Figure 1). 
        The types of KRAS alterations seen were missense alterations in 70% and amplifications in
37% of patients (ctDNA) versus 91% and 9%, respectively, in tissue (Supplemental Figure 2).
Altogether, 15 kinds of KRAS alterations were seen in this study (in ctDNA or tissue DNA): KRAS
amplification  (N=26);  KRAS A59T  (N=1);  KRAS D33E  (N=1);  KRAS  G12A (N=6);  KRAS G12C
(N=11); KRAS G12D (N=19); KRAS G12R (N=10); KRAS G12S (N=5); KRAS G12V (N=15); KRAS
G13D (N=10); KRAS K117N (N=2); KRAS Q61H (N=1); KRAS Q61K (N=1); KRAS Q61R (N=1); and
KRAS V14I (N=1).
Overall, 101 patients (23.3% of 433 tumors) harbored a KRAS alteration: 20 patients (4.6%
of 433) had KRAS found only in ctDNA; 45 (10.3% of 433) had KRAS only in tissue; and 36 (8.3%
of 433) in both (Supplemental Figure 1).
Overall Concordance 
Temporal effects and overall concordance:  Overall  concordance for  KRAS alterations in
blood ctDNA versus tissue was 85.0% (Table 2). When comparing the concordance rate between
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the 165 patients who had both ctDNA and tissue biopsy within 2 months of each other versus the
199 patients with the time period being >6 months, the concordance rate was 85.5% versus
83.4% (P=0.67)  (Table 2).   The concordance  rate  for  subtypes of  the more  common  KRAS
alterations was consistently over 90% regardless of the time interval between tissue and ctDNA
(Supplemental  Tables 1 and 2)  (keeping in  mind that, because of  the small  numbers  of
patients with each  KRAS alteration subtype,  the ability  to analyze statistical  differences was
limited).  
Spatial effects and overall concordance: Concordance between ctDNA and tissue for KRAS
alterations  was  not  dependent  on whether  the tissue biopsy  site  was primary  or  metastatic
disease (86.4% versus 83.4%; P=0.42) (Table 2).
Disease histology and overall concordance: Concordance rates for  KRAS alterations were
not statistically different in patients with colorectal versus non-colorectal cancers (77.8% versus
86.0%; P=0.15) (Supplemental Table 3). 
%ctDNA (variant allele frequency) and overall concordance: Concordance rate also did
not  differ  when  dichotomized  by  %ctDNA  (using  the  median  (1.55%)  %ctDNA  for  KRAS
alterations): 84.2% versus 90%;  P=0.66 (Supplemental Table 4) (but only small numbers of
patients were assessable).  
Positive concordance (effects of temporal, spatial, and histologic factors as well as
variant allele fraction)
 Figure 2 shows that positive concordance was  35.6%.  Positive concordance  decreased
from 46.7% to 21.4% when the time period between blood draw and tissue biopsy was ≤2
months versus over 6 months (P=0.02) (Table 2). Positive concordance did not differ depending
on whether the tissue biopsy was from the primary or metastatic site (29.5% versus 40.4%;
P=0.30) (Table 2). The positive concordance rate for KRAS alterations in colorectal cancer was
higher than in non-colorectal cancer (57.1% versus 27.4%, P=0.01) (Figure 2, Supplemental
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Table 3, and Supplemental Figure 3). %ctDNA was not correlated with positive concordance
(Supplemental Table 4); positive concordance was also similar (92.3% and 92.9%, respectively
for %ctDNA <1.55% and ≥1.55%) when only the 27 patients with ≤6 months between tests were
considered (data not shown).  
Accuracy of ctDNA for tissue DNA for KRAS alterations and vice versa
As mentioned earlier, the prevalence of  KRAS alterations in ctDNA was 12.9% while the
prevalence of  KRAS alterations in tissue was 18.7%.  Supplemental Table 5 shows that the
positive predictive power of ctDNA for tissue DNA positivity (which is equivalent to the sensitivity
of tissue for ctDNA. Supplemental Table 6) for KRAS alterations was 64.3%. When comparing
between the patients whose blood and tissue samples were ≤2 months apart and those with the
time period  being  >6 months,  the  value  was  84% and 40.9% (P=0.003).  Also,  the  positive
predictive power of tissue for ctDNA positivity (which is equivalent to the sensitivity of ctDNA for
tissue)  for  KRAS alterations  was  44.4%.  The  value  for  the  patients  whose  blood  and tissue
samples were ≤2 months apart versus >6 months apart was 51.2% versus 31%, respectively
(P=0.14).
In contrast, specificity and negative predictive power of ctDNA for tissue and vice versa
were  94.3%  and  88.1%  ,  and  did  not  differ  regardless  of  the  time  interval  between  tests
(Supplemental Tables 5 and 6).   
Survival analysis
Patients with discordant or absent KRAS alterations live longer when compared to
patients  with  concordant  KRAS  alterations  (N  =  433  patients): Univariate  and
multivariate  analyses  were  performed  to  determine  factors  associated  with  outcome.  In
multivariate  analysis  of  all  433  patients,  older  age  (≥60  years)  and  the  presence  of  KRAS
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alterations in both ctDNA and tissue (versus presence in one or the other or in neither) were
associated with a shorter OS (Table 3). The multivariate hazard ratios (HRs) (95% confidence
interval; P values) were 1.72 (1.04-2.86; P=0.04), 1.52 (0.94-2.46; P=0.09), and 1.70 (1.03-2.81;
P=0.04) when OS was measured from diagnosis, time of blood sample for ctDNA analysis, and
time  of  recurrent/metastatic  disease,  respectively.  Figure  3 further  demonstrates  that,
regardless of whether survival is measured from diagnosis, from blood draw, or from time of
advanced/metastatic  disease,  patients  with  concordant  (KRAS alterations  in  both  blood  and
tissue) versus discordant KRAS alterations (KRAS in blood or tissue but not both) live longer (all P
values significant or trend). Patients with concordant versus no KRAS alterations also live longer.
However, patients with discordant KRAS alterations show no difference in survival as compared
with  those  with  no  KRAS alterations.   The  observations  were analogous  when only  the 234
patients with ≤6 months between blood draw and tissue biopsy were evaluated (Supplemental
Figure 4).
In patients with KRAS alterations, those with discordant KRAS status live longer when
compared  to  patients  with  concordant  blood  and  tissue  KRAS  status  (N  =  101
patients):  The OS was significantly shorter (or trended to be shorter) (depending on the start
point of survival analysis) in univariate and multivariate analysis of factors affecting OS in the
101 patients with KRAS alterations, when comparing those with KRAS alterations in both blood
and tissue versus those with KRAS alterations in either blood or tissue, but not both (Figure 3
and Supplemental Table 7). Kaplan Meier curves demonstrate that these trends persist when
only  the  59  patients  with  KRAS alterations  and ≤6 months  between blood  draw and tissue
sample were analyzed—patients with KRAS alterations in both blood and tissue versus only blood
or only tissue had a trend toward shorter survival regardless of whether survival was measured
from  time  of  diagnosis,  time  of  ctDNA  blood  draw  or  time  of  recurrent/metastatic  disease
(Supplemental Figure 4: P=0.06, 0.06 and 0.16, respectively).  
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DISCUSSION
NGS has  unveiled  useful  genomic  biomarkers  for  predicting  diagnosis,  prognosis,  and
response  to  cancer  treatment.22-27 NGS  can  be  performed  on  either  tissue  or  blood-derived
ctDNA; these technologies may be complementary. Herein, by using the data from 433 patients
with diverse cancer types, we assessed the effect of temporal (time interval between tissue and
blood sample) and spatial (tissue from primary versus metastatic site) factors on concordance of
KRAS alterations in tissue and ctDNA, and their association with survival.
We found that 23.3% of diverse cancer patients had a  KRAS alteration; 12.9% in ctDNA
and 18.7% in tissue (8.3% in both). These percentages are consistent with a previous large-scale
survey  of  over  78,000  tumor  tissues  showing  KRAS alterations  in  22% of  cancers.28 In  our
dataset, genomic alterations (in either blood, tissue or both) were also commonly seen in TP53
(59.6% of  patients),  CDKN2A/B (20.6%),  and  EGFR (17.6%)  (Figure  1).  For  the  most  part,
alterations  in  ctDNA  and  tissue  were  found  in  a  similar  percentage  of  patients.  However,
CDKN2A/B loss was found in only 1.9% of patients in ctDNA, but in 20.3% of patients by tissue
NGS; this discrepancy is most likely due to the failure to capture allelic loss in older panels of
ctDNA sequencing. 
In regard to pathogenic  KRAS alterations, gene amplification and 14 kinds of mutation
were seen. Further studies may be required to determine whether the impact of these alterations
differs or not. Interestingly, a study in colorectal cancer showed that alterations that occurred in
codons 59, 61, 117, and 146 had higher MAPK activity than those in codons 12 and 13 and that
the mutations with higher MAPK activity were associated with a shorter survival.29 
The overall concordance rate for KRAS alterations in ctDNA and tissue was 85.0% (Table
2). When assessed according to subtype of KRAS alteration, the concordance rate was over 90%
for each subtype (Supplemental Tables 1 and 2). In terms of the temporal (≤2 months versus
>6 months between blood draw and tissue biopsy) and spatial (tissue biopsy site was primary
tumor versus metastatic sites) effects on the overall concordance rate, no statistical differences
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were observed (85.5% versus 83.4% [P=0.67], and 86.4% versus 83.4% [P=0.42], respectively).
Further, overall concordance did not vary by %ctDNA (Supplemental Table 4). However, the
overall  concordance  rates  were  largely  impacted  by  the  ctDNA-negative/tissue-negative
population. In fact, when limited to the patients with KRAS alterations, the positive concordance
rate (positive in both ctDNA and tissue divided by positive in ctDNA or positive in tissue or in
both)  was only 35.6% (Figure 2);  further,  KRAS alteration-positive concordance  significantly
decreased from 46.7% to 21.4% when the time period between blood draw and tissue biopsy
was ≤2 months versus >6 months (P=0.02); there was however no statistical difference when
tissue biopsy was from primary or metastatic site (Table 2). In comparison, a prior study in
colorectal  cancer also showed a high overall  concordance rate (~90%) for  RAS alterations in
ctDNA versus tissue18; although positive concordance was not formally analyzed, that study did
demonstrate that some patients had discordant results, albeit at a lesser frequency than in our
study, perhaps because the population was limited to colorectal cancer or because the blood and
tissue samples were taken at time points close together. Indeed, in our patients, the positive
concordance rate for  KRAS  alterations in colorectal  cancer was higher than in non-colorectal
cancer (57.1% versus 27.4%, P=0.01) (Figure 2). 
The positive predictive power of ctDNA for tissue DNA positivity (= the sensitivity of tissue
for ctDNA) was 64.3% for detecting  KRAS alterations (Supplemental Tables 5 and  6).  This
means that,  of  the  KRAS-altered ctDNA tests,  64.3% were positive by tissue.  The value was
substantially lower when blood and tissue samples were >6 months apart than when they were
≤2 months apart (40.9% versus 84.0%;  P=0.003). The positive predictive power of tissue for
ctDNA positivity (= the sensitivity of ctDNA for tissue) was 44.4%. This means that, of the KRAS-
altered tissue tests, 44.4% were positive by ctDNA. This value also showed a trend to be lower
when blood and tissue samples were >6 months apart than when they were ≤2 months apart
(31.0% versus 51.2%;  P=0.14).  Hence,  substantial  numbers of  the  KRAS-altered ctDNA tests
were  not  picked  up  by  tissue  testing  and vice  versa;  further,  in  each  case,  this  dichotomy
increased with greater time interval between the blood sample and tissue biopsy dates (albeit
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the increase in discrepancy was only statistically significant for the ctDNA tests that were not
picked up by tissue). In contrast, specificity and negative predictive power of ctDNA for tissue (=
the negative predictive power and specificity of tissue for ctDNA, respectively) remained high
(94.3% and 88.1%), regardless of the time interval between tests. These findings suggested that,
if one test (ctDNA or tissue DNA) showed negative for  KRAS alterations, the other would also
show negative, regardless of the time interval. 
In the multivariate analysis of all 433 patients, the presence of  KRAS alterations in both
ctDNA and tissue (versus not [“not” means the presence of  KRAS alterations in tissue alone,
blood alone, or neither]) was an independent poor prognostic factor for patients’ overall survival,
even if the time interval between blood draw and tissue biopsy was considered as a confounder
(Table 3). Interestingly, the survival of patients with no KRAS alterations did not differ from that
of patients with discordant KRAS alterations, while the survival of patients with concordant KRAS
alterations in ctDNA and tissue was significantly worse (Figure 3). A prior systematic review
analyzing ctDNA results in diverse cancer patients showed that KRAS alterations were associated
with a poorer overall survival (HR=2.02, 95%CI 1.63–2.51).30 However, our findings suggested
that  KRAS alterations in both tests were more meaningful as a prognostic factor.  In addition,
even among 101 patients with KRAS alterations, the presence of KRAS alterations in both ctDNA
and tissue (i.e., concordant) still tended to be a strong prognostic factor for poor survival (the
HRs ranged 1.81 to 2.30 [P-values 0.02-0.13],  Figure 3 and Supplemental Table 7).  It  is
unclear  why  concordant  blood  and  tissue  alterations  are  associated  with  poorer  survival.
Alterations were not more concordant with higher %ctDNA (Supplemental Table 4), which has
previously  been  shown  to  be  associated  with  poorer  survival.8 To  our  knowledge,  this
phenomenon is not previously reported and, hence, deserves additional investigation.   
 There were several limitations in this study. First, prior treatment type at time of blood
draw or tissue biopsy was not considered. It was previously reported that KRAS status in ctDNA
could be affected by specific therapeutic pressure such as administration of EGFR antibodies.31, 32
Indeed,  7  out  of  20  patients  who  had  KRAS alterations  only  in  ctDNA  received  anti-EGFR
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therapies prior to their ctDNA analyses in this series. Moreover, 3 additional patients received
systemic  therapies  with  other  targeted  agents,  which  may  lead  to  the  emergence  of  KRAS
alterations as  a mechanism of  acquired resistance.  Second,  the number of  samples in each
cancer type depended on the physician choice to examine ctDNA or tissue by NGS.  Third, the
tissue  and  ctDNA  tests  were  performed  by  different  vendors,  though  this  could  also  be
considered an advantage of the study in that it permitted a comprehensive comparison (which is
a topic of interest to the liquid biopsy field).   Finally, while %ctDNA was not associated with
concordance,  the number of patients evaluable was small  (since, by definition,  only patients
positive for KRAS in ctDNA could be assessed) and may have precluded robust comparisons.
In conclusion, KRAS alterations were seen in 23.3% of pan-cancer patients and the overall
concordance between ctDNA and tissue was 85.0%. Temporal and spatial effects did not impact
the overall concordance of KRAS alterations. High overall concordance was mainly driven by the
fact  that,  if  either  blood  or  tissue  was  negative  for  a  KRAS alteration,  the  other  was  likely
negative as well.  In  contrast,  substantial  numbers of  the  KRAS-altered ctDNA tests  were not
picked up by tissue testing and vice versa.  Positive concordance was significantly higher when
the time interval between blood draw and tissue biopsy was <2 months versus >6 months. This
result  is  consistent  with  prior  studies  that  show  that  tumors  evolve  over  time.33 Positive
concordance was also higher in colorectal cancer versus other tumors. Importantly, concordance
for  KRAS alteration positivity between blood and ctDNA was an independent factor associated
with a significantly worse survival  as compared to patients with no  KRAS  alterations or with
discordant KRAS alterations.  Further studies are warranted to evaluate the prognostic impact of
concordance between blood and tissue sequencing for other molecular alterations.
17
REFERENCES
1. Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J, Kim J. Prognostic and predictive roles of 
KRAS mutation in colorectal cancer. International journal of molecular sciences 2012;13: 12153-68.
2. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. 
KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted
pathway inhibitors. PloS one 2012;7: e38033.
3. Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. British journal of cancer 2014;111:
817-22.
4. Kurzrock R, Giles FJ. Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. Cell 
cycle (Georgetown, Tex) 2015;14: 2219-21.
5. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, et 
al. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer research 2016;76: 3690-701.
6. Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, Draganic B, Smith S, Hewitt C, Philimore H, Lucas A, Shi E,
et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from 
circulating tumor DNA and tissue-based RAS testing. Molecular oncology 2017;11: 208-19.
7. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-
Llorca F, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer research 2006;66: 
3992-5.
8. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock 
R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2016;22: 5497-505.
9. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock 
R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget 
2016;7: 9707-17.
10. Kidess-Sigal E, Liu HE, Triboulet MM, Che J, Ramani VC, Visser BC, Poultsides GA, Longacre TA, Marziali A, Vysotskaia V, 
Wiggin M, Heirich K, et al. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free 
platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget 2016;7: 85349-64.
11. Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, 
Wotherspoon A, Capdevila J, et al. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. 
Scientific reports 2018;8: 1445.
12. Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao M, Zhu Y, 
Zhou C, et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in 
NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2015;21: 3196-203.
13. Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, et
al. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer 
Institute 2017;109.
18
14. Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL, Lima-Oliveira G, Gusella M, Pasini F, Lippi G, 
Guidi GC. Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with 
colorectal cancer. PloS one 2015;10: e0126417.
15. Schwaederle MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. Utility of 
Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clinical 
cancer research : an official journal of the American Association for Cancer Research 2017;23: 5101-11.
16. Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi 
N, Zhao J, et al. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology 
2019;156: 108-18.e4.
17. Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R. Analysis 
of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric 
Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2018;24: 6248-56.
18. Grasselli J, Elez E, Caratu G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Vieitez JM, Paez D, Falco E, Lopez Lopez C, et 
al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. 
Annals of oncology : official journal of the European Society for Medical Oncology 2017;28: 1294-301.
19. Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DS, Kopetz ES, Lee J, 
Nikolinakos PG, et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of 
Cell-Free Circulating Tumor DNA. PloS one 2015;10: e0140712.
20. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F,
et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature 
biotechnology 2013;31: 1023-31.
21. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. On the Road to 
Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Molecular cancer therapeutics 2015;14: 
1488-94.
22. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. Hypermutated Circulating 
Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clinical cancer research : an official journal of 
the American Association for Cancer Research 2017;23: 5729-36.
23. Ikeda S, Schwaederle M, Mohindra M, Fontes Jardim DL, Kurzrock R. MET alterations detected in blood-derived circulating 
tumor DNA correlate with bone metastases and poor prognosis. Journal of hematology & oncology 2018;11: 76.
24. Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. Association of Biomarker-
Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. 
JAMA oncology 2016;2: 1452-9.
25. Kato S, Janku F. Cell-free DNA as a novel marker in cancer therapy. Biomarkers in medicine 2015;9: 703-12.
26. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, 
Bazhenova L, Kurzrock R. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation 
Sequencing. Cancer research 2017;77: 5419-27.
27. Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R. 
Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer research 2017;77: 
4238-46.
28. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer research 2012;72: 2457-67.
19
29. Loree JM, Miron B, Holla V, Overman MJ, Pereira AAL, Lam M, Morris VK, Raghav KPS, Routbort M, Shaw KR, Burck N, 
Sharivkin R, et al. Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS 
mutations. Journal of Clinical Oncology 2017;35: 3589-.
30. Zhuang R, Li S, Li Q, Guo X, Shen F, Sun H, Liu T. The prognostic value of KRAS mutation by cell-free DNA in cancer 
patients: A systematic review and meta-analysis. PloS one 2017;12: e0182562.
31. Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, et al. 
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a 
study on circulating tumor DNA. Oncotarget 2017;8: 13611-9.
32. Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodriguez C, Brozos E, Vidal Y, Candamio 
S, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. 
Annals of oncology : official journal of the European Society for Medical Oncology 2017;28: 1325-32.
33. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer research 2012;72: 4875-82.
20
FIGURE LEGENDS
Figure 1. Frequent alterations among blood-derived ctDNA and tissue biopsy (N=433).  
Percentage denotes percent of patients with an alteration.  Most common alterations in both ctDNA and tissue in 433 patients with 
diverse cancers who had both ctDNA and tissue biopsy are shown. VUS alterations were excluded. If two different samples were 
collected for a patient, only the tissue and blood samples closest together timewise were counted.
Figure 2. KRAS alterations among 433 patients, categorized by colorectal cancer and non-colorectal cancers for patients with ≤2 
months, >2-6 months, and >6 months between blood draw and tissue biopsy. 
If two different samples were collected for a patient, only the tissue and blood samples closest together timewise were counted. 
Numbers in parentheses represent number of patients.
Figure 3. Survival analysis among patients with concordant KRAS alterations, those with discordant KRAS alterations, and those with
no KRAS alterations (N=433 patients). 
Panel 3A. Overall survival from date of diagnosis; 
Panel 3B. Overall survival from date of blood draw for ctDNA test; 
Panel 3C. Overall survival from date of metastatic or recurrent disease. *Twenty-eight patients were excluded from this analysis 
because their disease was surgically resected.
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FIGURES
Figure 1. Frequent alterations among blood-derived ctDNA and tissue biopsy (N=433).   
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Figure 2: KRAS alterations among 433 patients, categorized by colorectal cancer and non-colorectal cancers for patients with ≤2 
months, >2-6 months, and >6 months between blood draw and tissue biopsy (see also Supplemental Figure 3).
23
24
Figure 3. Survival analysis among patients with concordant KRAS alterations, those with 
discordant KRAS alterations, and those with no KRAS alterations (N=433 patients). 
Panel 3A. Overall survival from date of diagnosis; 
Panel 3B. Overall survival from date of blood draw for ctDNA test; 
Panel 3C. Overall survival from date of metastatic or recurrent disease. *Twenty-eight patients 
were excluded from this analysis because their disease was surgically resected.
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TABLES
Table 1. Patient characteristics among the 433 patients that had both blood-derived ctDNA and 
tissue testing done.
Patient Characteristics Total Patients
N=433
Age at diagnosis (years: median, range) 59 (2-91)
Gender (N, %)  
    Women 237 (54.7%)
    Men 196 (45.3%)
Type of cancer (N, %)  
    Gastrointestinal* 104 (24.0%)
    Lung 78 (18.0%)
    Brain 56 (12.9%)
    Breast 50 (11.5%)
    Hepatic/pancreatic/biliary 40 (9.2%)
    Head and neck 31 (7.2%)
    Gynecologic 22 (5.1%)
    Others** 52 (12.0%)
Tissue Biopsy Site (N, %)  
    Liver 63 (14.5%)
    Brain 59 (13.6%)
    Lung 54 (12.5%)
    Gastrointestinal 51 (11.8%)
    Lymph node 18 (4.2%)
    Breast 13 (3.0%)
    Gynecologic 13 (3.0%)
    Others 162 (37.4%)
Time between tissue biopsy and blood draw 
for ctDNA
    Median months (interquartile range) 5.0 (0.03-241)
    Category (N, %)
        ≤2 months 165 (38.1%)
        >2-6 months 69 (15.9%)
        >6 months 199 (46.0%)
 *Includes colorectal cancer (N=54), appendiceal cancer (N=20), gastric cancer (N=8), 
esophageal cancer (N=7), gastrointestinal stromal tumor (N=7), anal cancer (N=3), small bowel 
cancer (N=3), and neuroendocrine tumor (N=2).
**Includes genitourinary/prostate cancers (N=16), cancers of unknown primary (N=10), soft 
tissue sarcoma (N=8), hematologic malignancies (N=7), mesothelioma/peritoneal carcinoma 
(N=5), skin carcinoma (N=4), and thymoma (N=2).
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Table 2. Overall concordance of KRAS alterations in all patients (N=433) and positive concordance in patients with KRAS alterations 
(N = 101), both stratified by time between blood draw and tissue biopsy (≤2, 2-6, and > 6 months) and by tissue biopsy site 
(primary tumor versus metastatic sites).  
All Patients (N=433)
Tissue DNA results Overall
concordance rate
Kappa
(SE)
Positive
concordance rate*Positive Negative
ctDNA
results
Positive 36 20
85.0% 0.44(0.06) 35.6%Negative 45 332
Temporal and Spatial Effects on Concordance 
Test results 
(ctDNA / tissue DNA) Overall concordance Positive concordance*
(+/
+)
(+/- plus -/
+) (-/-) Rate
Kappa
(SE) P-value Rate P-value
Time interval
between 
blood draw 
and tissue 
biopsy 
(months)
≤2 months 
(N=165) 21 24 120 85.5% 0.55 (0.08) 0.67 (≤2 vs.
>6) 
0.42 (≤6 vs.
>6)
46.7
% 0.02 (≤2 vs.
>6 months)
0.02 (≤6 vs.
>6 months)
>2-6 months 
(N=69) 6 8 55 88.4% 0.53 (0.15)
42.9
%
>6 months 
(N=199) 9 33 157 83.4% 0.26 (0.09)
21.4
%
Tissue biopsy
site
Primary (N = 
228) 13 31 184 86.4% 0.38 (0.09)
0.42
29.5
%
0.30
Metastatic 
(N=205) 23 34 148 83.4% 0.48 (0.08)
40.4
%
 *Positive concordance rate =  (positive∈bothctDNA∧tissue DNA)
(positive∈either ctDNA∨tissueDNA∨¿both)
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Table 3. Factors associated with survival from date of diagnosis, date of blood draw for ctDNA test, and from date of 
metastatic/recurrent disease (N = 433 patients).  
Univariate Multivariate*
Variables 
Median OS
(months) HR (95% CI)
P-
value HR (95% CI) 
P-
value
OS from date of diagnosis
Age
    ≥60 years (N=199) vs. <60 years (N=234)
 
57.6 vs.
103.8
 
1.84 (1.40 -
2.43)
 <
0.001
 
1.99 (1.50 -
2.64)
 
<
0.001
Gender
    Women (N=237) vs. Men (N=196)  78.1 vs. 
68.0
 
0.95 (0.72 -
1.24)  0.69
- -
Type of cancer
    GI or HPB (N=144) vs. Not (N=289)     53.2 vs. 88.8
 
1.65 (1.24 -
2.18)
 <
0.001
 
1.47 (1.08 -
1.99)
 
0.01
Time interval between tissue biopsy and 
blood draw 
    ≤6 months (N=234) vs. >6 months (N=199)
 
65.1 vs. 85.1
 
1.41 (1.08 -
1.84)
 
0.01
 
1.43 (1.09 -
1.88)
 
0.009
KRAS alteration seen in ctDNA and/or tissue
DNA
    Yes (N=101) vs. No (N=332)
 
73.5 vs. 78.1
 
1.21 (0.89 -
1.66)
 
0.23 - -
KRAS alteration seen in both ctDNA and 
tissue DNA
    Yes (N=36) vs. Not (N=397)
 
32.2 vs. 78.1
 
1.98 (1.26 -
3.12)
 
0.003
 
1.72 (1.04 -
2.86)
 
0.04
 OS from date of blood draw for ctDNA test
Age
    ≥60 years (N=199) vs. < 60 years (N=234) 13.7 vs. 21.8
 
1.34 (1.03 -
1.75) 0.03
1.37 (1.05 -
1.80) 0.02
Gender
    Women (N=237) vs. Men (N=196)  18.0 vs. 21.8
 
1.05 (0.81 -
1.38)
 
0.71 - -
Type of cancer
    GI or HPB (N=144) vs. Not (N=289)     13.3 vs. 18.8
 
1.31 (0.99 -
1.72)
 
0.06
 
1.21 (0.90 -
1.62)
 
0.21
Time interval between tissue biopsy and 
blood draw 
 
17.2 vs. 18.8
 
1.07 (0.81 -
 
0.65
- -
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    ≤6 months (N=234) vs. >6 months (N=199) 1.39)
KRAS alteration seen in ctDNA and/or tissue
DNA
    Yes (N=101) vs. No (N=332)
 
15.0 vs. 18.2
 
1.19 (0.87 -
1.63)
 
0.27 - -
KRAS alteration seen in both ctDNA and 
tissue DNA
    Yes (N=36) vs. Not (N=397)
 
9.0 vs. 18.8
 
1.61 (1.03 -
2.53)
 
0.04
 
1.52 (0.94 -
2.46)
 
0.09
OS from date of metastatic or recurrent disease**
Age
    ≥60 years (N=185) vs. <60 years (N=220)  30.0 vs. 44.2
 
1.54 (1.18 -
2.02)
 
0.001
 
1.66 (1.26 -
2.18)
 
<
0.001
Gender
    Women (N=222) vs. Men (N=183)  42.1 vs. 35.1
 
0.82 (0.63 -
1.08)
 
0.16 - -
Type of cancer
    GI or HPB (N=137) vs. Not (N=268)     32.2 vs. 43.6
 
1.56 (1.18 -
2.06)
 
0.002
 
1.45 (1.07 -
1.96)
 
0.02
Time interval between tissue biopsy and 
blood draw 
    ≤6 months (N=221) vs. >6 months (N=184)
 
34.9 vs. 43.4
 
1.46 (1.12 -
1.92)
 
0.006
 
1.48 (1.13 -
1.94)
 
0.005
KRAS alteration seen in ctDNA and/or tissue
DNA
    Yes (N=97) vs. No (N=308)
 
35.5 vs. 40.7
 
1.19 (0.86 -
1.62)
 
0.29 - -
KRAS alteration seen in both ctDNA and 
tissue DNA
    Yes (N=36) vs. Not (N=369)
 
25.9 vs. 41.7
 
1.98 (1.26 -
3.13)
 
0.003
 
1.70 (1.03 -
2.81)
 
0.04
 *P-values <0.15 in univariate were selected for multivariate analysis. 
**A total of 28 patients were excluded from the latter analysis because their disease was surgically resected.
Abbreviations: CI, confidence interval; GI, gastrointestinal; HPB, hepatic/pancreatic/biliary; HR, hazard ratio; NGS, next-generation 
sequencing; OS, overall survival.
SUPPLEMENTRY FILES
Supplemental Table 1.  Concordance between tissue DNA and ctDNA for KRAS amplification for patients with ≤2 months, >2-6 
months, and >6 months between a tissue biopsy and blood-derived ctDNA.
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KRAS Amplification
(+/
+)
(-/-
)
Overall
concordan
ce
Kappa
(SE)
P-value All patients (N=433) 2 407 94.5%
0.12
(0.09)
Time interval 
between blood
draw and 
tissue biopsy 
(months)
≤2 
(N=165) 1 157 95.8%
0.20
(0.19) 0.37 (≤2 vs.
>6) 
0.53 (≤6 vs.
>6)
>2-6 
(N=69) 1 64 94.2%
0.31
(0.25)
>6 
(N=199) 0 186 93.5%
0.01
(0.01)
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Supplemental Table 2.  Concordance between tissue DNA and ctDNA for KRAS G12D, G12V, 
G12C, G12R and G13D alterations for patients ≤2 months, 2-6 months, and > 6 months between
a tissue biopsy and blood-derived ctDNA.*
KRAS G12D
(+/
+)
(-/-
)
Overall
Concordan
ce
Kappa
(SE)
P-value All patients (N=433) 4
41
4 96.5%
0.34
(0.13)
Time interval 
between 
tissue biopsy 
and blood 
draw (months)
≤2 
(N=165) 3
15
4 95.2%
0.41
(0.16)
0.27 (≤2 vs. >6
months) 
0.43 (≤6 vs. >6
months)
>2-6 
(N=69) 0 67 97.1% -
>6 
(N=199) 1
19
3 97.5%
0.28
(0.22)
KRAS G12V
(+/
+)
(-/-
)
Overall
Concordan
ce
Kappa
(SE)
P-value All patients (N=433) 9
41
8 98.6%
0.74
(0.10)
Time interval 
between 
tissue biopsy 
and blood 
draw (months)
≤2 
(N=165) 2
15
8 97.0%
0.43
(0.21)
0.10 (≤2 vs. >6
months) 
0.23 (≤6 vs. >6
months)
>2-6 
(N=69) 2 67 100%
1.00
(0.00)
>6 
(N=199) 5
19
3 99.5%
0.91
(0.09)
KRAS G12C
(+/
+)
(-/-
)
Overall
Concordan
ce
Kappa
(SE)
P-value All patients (N=433) 3
42
2 98.2%
0.42
(0.17)
Time interval 
between 
tissue biopsy 
and blood 
draw (months)
≤2 
(N=165) 3
16
0 98.8%
074
(0.17)
0.46 (≤2 vs. >6
months) 
0.48 (≤6 vs. >6
months)
>2-6 
(N=69) 0 68 98.6% -
>6 
(N=199) 0
19
4 97.5%
0.01
(0.01)
KRAS G12R
(+/
+)
(-/-
)
Overall
Concordan
ce
Kappa
(SE)
P-value All patients (N=433) 3
42
3 98.4%
0.46
(0.17)
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Time interval 
between 
tissue biopsy 
and blood 
draw (months)
≤2 
(N=165) 3
16
0 98.8%
0.74
(0.17)
0.69 (≤2 vs. >6
months) 
0.71 (≤6 vs. >6
months)
>2-6 
(N=69) 0 68 98.6% -
>6 
(N=199) 0
19
5 98.0% -
KRAS G13D
(+/
+)
(-/-
)
Overall
Concordan
ce
Kappa
(SE)
P-value All patients (N=433) 6
42
3 99.1%
0.75
(0.12)
Time interval 
between 
tissue biopsy 
and blood 
draw (months)
≤2 
(N=165) 3
16
1 99.4%
0.85
(0.14)
0.63 (≤2 vs. >6
months) 
0.34 (≤6 vs. >6
months)
>2-6 
(N=69) 2 67 100%
1.00
(0.00)
>6 
(N=199) 1
19
5 98.5%
0.39
(0.28)
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Supplemental Table 3. Concordance for KRAS alterations in tissue versus ctDNA by type of cancer. 
Test results 
(ctDNA / tissue DNA) Overall concordance
Positive
concordance
(+/
+)
(+/- plus
-/+)
(-/-
) Rate
Kappa
(SE) P-value Rate P-value
Colorectal cancer patients 
(N=54) 16 12 26 77.8% 0.55 (0.11)
0.15
57.1
%
0.01
Non-colorectal cancer patients 
(N=379) 20 53 306 86.0% 0.35 (0.07)
27.4
%
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Supplemental Table 4. Concordance between tissue and blood KRAS alterations based on 
%ctDNA (dichotomized at median %ctDNA for KRAS alterations).*
Tissue DNA
results
<1.55% ctDNA 
(N=19)
Positiv
e
Negati
ve
Overall
concordan
ce
Positive 
concordan
ce
Kappa
(SE)
P-
value
ctDNA
results
Positive 16 3
84.2% 84.2% -
0.66
Negativ
e 0 0
≥1.55% ctDNA 
(N=20) 
Positiv
e
Negati
ve
Overall
concordan
ce
Positive
concordan
ce
Kappa
(SE)
ctDNA
results
Positive 18 2
90.0% 90.0% -Negativ
e 0 0
*Among 56 patients with KRAS alterations in ctDNA, 39 patients were available for %ctDNA (17 
patients had only KRAS amplifications and %ctDNA was not evaluated for amplifications). In 
these 39 patients, the median %ctDNA of KRAS alterations was 1.55% (range, 0.1% - 32.7%); the
Kappa values could not be calculated due to ‘ctDNA negative = 0’.  Note that concordance may 
be biased in this analysis because, by definition, in this analysis, all patients had KRAS 
alterations in ctDNA.
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Supplemental Table 5.  Accuracy of ctDNA for tissue DNA results*
Stratified by time
interval 
Parameters
Generato
r
All
patients
(N=433)
≤2
months
(N=165)
>6
months
(N=199) P-value
Sensitivity A / (A + B) 44.4% 51.2% 31.0% 0.14
Positive predictive 
value A / (A + C) 64.3% 84.0% 40.9% 0.003
Specificity D / (C +D) 94.3% 96.8% 92.4% 0.13
Negative predictive 
value
D / (B +
D) 88.1% 85.7% 88.7% 0.50
*The table below was used to generate the numbers in Supplemental Tables 5 and 6
Tissue
Positive Negative 
ctDNA Positive A C
Negative B D
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Supplemental Table 6. Accuracy of tissue DNA for ctDNA results*
Stratified by time
interval 
Parameters Generator
All
patients
(N=433)
≤2
months
(N=165)
>6
months
(N=199) P-value
Sensitivity A / (A + C) 64.3% 84.0% 40.9% 0.003
Positive predictive value A / (A + B) 44.4% 51.2% 31.0% 0.14
Specificity D / (B + D) 88.1% 85.7% 88.7% 0.50
Negative predictive 
value D / (C + D) 94.3% 96.8% 92.4% 0.13
*The table below was used to generate the numbers in Supplemental Tables 5 and 6
Tissue
Positive Negative 
ctDNA Positive A C
Negative B D
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Supplemental Table 7. Investigation of factors associated with overall survival from date of diagnosis, from date of blood draw for 
ctDNA test, and from date of metastatic or recurrent disease among 101 patients with KRAS alterations in either ctDNA or tissue 
DNA. 
Univariate Multivariate*
Variables 
Median OS
(months) HR (95% CI)
P-
value HR (95% CI) P-value
OS from date of diagnosis
Age
    ≥60 years (N=46) vs. <60 years (N=55)
 
59.3 vs.
78.5
1.46 (0.84 -
2.56) 0.18
- -
Gender
    Women (N=48) vs. Men (N=53)  78.5 vs.60.6 0.86 (0.49 -1.50) 0.58
- -
Type of cancer  
    GI or HPB (N=64) vs. Not (N=37)    
 
59.3 vs.
81.8
1.58 (0.86 -
2.90) 0.14
1.17 (0.58 -
2.38) 0.66
Time interval between tissue biopsy and blood 
draw 
    ≤6 months (N=59) vs. >6 months (N=42)
 
53.2 vs.
73.5
1.16 (0.66 -
2.03) 0.61
- -
KRAS concordance between both ctDNA and 
tissue DNA
    Concordant (N=36) vs. Discordant (N=65)
 
32.2 vs.77.2 1.96 (1.11 -3.45) 0.02
1.81 (0.93 -
3.50) 0.08
 OS from date of blood draw for ctDNA test
Age
    ≥60 years (N=46) vs. <60 years (N=55)
 
10.0 vs.
19.5
1.42 (0.81 -
2.47) 0.22
- -
Gender
    Women (N=48) vs. Men (N=53)  18.0 vs.14.6 0.93 (0.54 -1.62) 0.81
- -
Type of cancer  
    GI or HPB (N=64) vs. Not (N=37)     19.5 vs. 9.2 0.77 (0.42 -1.39) 0.38
- -
Time interval between tissue biopsy and blood 
draw 
    ≤6 months (N=59) vs. >6 months (N=42)
 
20.5 vs.10.0 0.77 (0.44 -1.35) 0.36
- -
KRAS concordance between both ctDNA and  - -
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tissue DNA
    Concordant (N=36) vs. Discordant (N=65) 9.0 vs.24.2
1.53 (0.88 -
2.68) 0.13
OS from date of metastatic or recurrent disease**
Age
    ≥60 years (N=45) vs. <60 years (N=52)  23.1 vs.40.5 1.52 (0.87 -2.65) 0.14
1.93 (1.08 -
3.45) 0.03
Gender
    Women (N=47) vs. Men (N=50)
 
34.4 vs.
39.5
0.96 (0.55 -
1.66) 0.87
- -
Type of cancer  
    GI or HPB (N=61) vs. Not (N=36)    
 
34.4 vs.
41.7
1.24 (0.69 -
2.24) 0.46
- -
Time interval between tissue biopsy and blood 
draw 
    ≤6 months (N=56) vs. >6 months (N=41)
 
26.9 vs.
41.7
1.60 (0.90 -
2.82) 0.11
1.49 (0.83 -
2.66) 0.18
KRAS concordance between both ctDNA and 
tissue DNA
    Concordant (N=36) vs. Discordant (N=61)
 
25.9 vs.
41.7
2.05 (1.14 -
3.68) 0.02
2.30 (1.23 -
4.30) 0.009
*P values <0.15 in univariate were selected for multivariate analysis.
**a total of four patients were excluded from this analysis because their disease was surgically resected. 
Abbreviations: CI, confidence interval; GI, gastrointestinal; HPB, hepato-pancreato-biliary; HR, hazard ratio; NGS, next-generation 
sequencing; OS, overall survival.
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Supplemental Figure 1. Consort flow diagram that shows the detection of the KRAS alteration 
in both tissue and ctDNA tests among patients with diverse cancers at the UC San Diego Moores 
Cancer Center. 
40
Supplemental Figure 2. Types of KRAS alteration. VUS alterations were excluded. If two 
different samples were collected for a patient, only the tissue and blood samples closest together
timewise were counted. 
Panel 2A. In ctDNA (N=56). 
41
Panel 2B. In tissue DNA (N=81).  Multiple alterations refers to both amplification and missense 
in the sample
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Supplemental Figure 3: KRAS alterations among 433 patients, categorized by colorectal 
cancer and non-colorectal cancers for patients with ≤6 months and >6 months between blood 
draw and tissue biopsy. If two different samples were collected for a patient, only the tissue and 
blood samples closest together timewise were counted. Numbers in parentheses represent 
number of patients.
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Supplemental Figure 4. Survival analysis between patients with concordant KRAS alterations 
(N = 27), those with discordant KRAS alterations (N = 32), and those with no KRAS alterations (N 
= 175) among 234 patients with ≤6 months between blood draw and tissue sample.
Panel 4A. Overall survival from date of diagnosis; 
Panel 4B. Overall survival from date of blood draw for ctDNA test; 
Panel 4C. Overall survival from date of metastatic or recurrent disease. *Thirteen patients were 
excluded from this analysis because their disease were surgically resected.
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